CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.

Product information

CAS Number: 501935-96-2

Molecular Weight: 234.26

Formula: C14H10N4

Chemical Name: 3, 6-diaminoacridine-9-carbonitrile

Smiles: NC1C=C2N=C3C=C(N)C=CC3=C(C#N)C2=CC=1

InChiKey: PUMGFEMNXBLDKD-UHFFFAOYSA-N

InChi: InChI=1S/C14H10N4/c15-7-12-10-3-1-8(16)5-13(10)18-14-6-9(17)2-4-11(12)14/h1-6H,16-17H2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

CTX1 binds directly to HdmX to prevent p53-HdmX complex formation, resulting in the rapidly induction of p53 in a DNA damage-independent manner.

In Vivo:

CTX1 ( (30 mg/kg; i.p.; five days a week; for 3 weeks) significantly enhances the survival of mice in AML model system. CTX1 exhibited significant anti-cancer activity alone as well as in combination with nutlin-3.

References:

1. Karan G, et al. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Mol Cancer Ther. 2016 Apr;15(4):574-582.

Products are for research use only. Not for human use.